Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cell and tissue combo devices

This article was originally published in The Gray Sheet

Executive Summary

CDRH will take the lead in reviewing human cell sorters for in vitro diagnostics, while the Center for Biologics Evaluation and Research has jurisdiction over devices that process cells or tissue for therapeutic readministration, according to a July 1jurisdictional update from FDA's Office of Combination Products. Products in the latter category include devices that isolate and concentrate a patient's stem cells before reinjection, as well as devices that process autologous blood or tissue to produce tissue engineered therapies (2"The Gray Sheet" March 5, 2007, p. 14)...

You may also be interested in...



Stem Cell Therapy Needs More Than Just The Cells: Device Firms See Opening

The advent of stem cell therapy to future medicine will be facilitated by medical devices that actually process and store the cells. At least two firms already see near-term opportunities to pioneer the technology

FDA Slacking In NDI Notification Enforcement; COVID-19 'Is Not An Excuse’ – NPA

In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.

Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far

Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.

UsernamePublicRestriction

Register

SC066183

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel